GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anthera Pharmaceuticals Inc (OTCPK:ANTH) » Definitions » E10

Anthera Pharmaceuticals (Anthera Pharmaceuticals) E10 : $0.00 (As of Mar. 2018)


View and export this data going back to 2010. Start your Free Trial

What is Anthera Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Anthera Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2018 was $-0.420. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.00 for the trailing ten years ended in Mar. 2018.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-04-30), Anthera Pharmaceuticals's current stock price is $0.0001. Anthera Pharmaceuticals's E10 for the quarter that ended in Mar. 2018 was $0.00. Anthera Pharmaceuticals's Shiller PE Ratio of today is .


Anthera Pharmaceuticals E10 Historical Data

The historical data trend for Anthera Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anthera Pharmaceuticals E10 Chart

Anthera Pharmaceuticals Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -22.77 -20.03 - - -

Anthera Pharmaceuticals Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Anthera Pharmaceuticals's E10

For the Biotechnology subindustry, Anthera Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anthera Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anthera Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Anthera Pharmaceuticals's Shiller PE Ratio falls into.



Anthera Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Anthera Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2018 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2018 (Change)*Current CPI (Mar. 2018)
=-0.42/105.2895*105.2895
=-0.420

Current CPI (Mar. 2018) = 105.2895.

Anthera Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
200806 0.000 92.320 0.000
200809 -232.191 92.307 -264.848
200812 -167.381 88.697 -198.692
200903 -164.480 89.744 -192.971
200906 -142.720 91.003 -165.125
200909 -151.680 91.120 -175.268
200912 -57.600 91.111 -66.563
201003 -53.120 91.821 -60.912
201006 -23.040 91.962 -26.379
201009 -23.040 92.162 -26.322
201012 -23.040 92.474 -26.233
201103 -35.840 94.283 -40.024
201106 -42.240 95.235 -46.700
201109 -38.400 95.727 -42.236
201112 -52.320 95.213 -57.857
201203 -32.640 96.783 -35.509
201206 -27.443 96.819 -29.844
201209 -11.040 97.633 -11.906
201212 -7.040 96.871 -7.652
201303 -3.920 98.209 -4.203
201306 -3.440 98.518 -3.676
201309 -2.400 98.790 -2.558
201312 -3.840 98.326 -4.112
201403 -3.120 99.695 -3.295
201406 -2.720 100.560 -2.848
201409 -2.480 100.428 -2.600
201412 -2.560 99.070 -2.721
201503 -2.240 99.621 -2.367
201506 -2.000 100.684 -2.091
201509 -2.320 100.392 -2.433
201512 -1.440 99.792 -1.519
201603 -2.340 100.470 -2.452
201606 -2.790 101.688 -2.889
201609 -4.850 101.861 -5.013
201612 -2.880 101.863 -2.977
201703 -2.030 102.862 -2.078
201706 0.030 103.349 0.031
201709 -0.580 104.136 -0.586
201712 -0.730 104.011 -0.739
201803 -0.420 105.290 -0.420

Add all the adjusted EPS together and divide 10 will get our e10.


Anthera Pharmaceuticals  (OTCPK:ANTH) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Anthera Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Anthera Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Anthera Pharmaceuticals (Anthera Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
25801 Industrial Boulevard, Suite B, Hayward, CA, USA, 94545
Anthera Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. The company currently has one Phase 3-ready clinical program and two Phase 2 clinical programs. It was established in 2004.
Executives
Christopher S Henney director 10505 ROSELLE STREET, SAN DIEGO CA 92121
Shanahan William R Jr officer: Chief Medical Officer 10301 STELLA LINK HOUSTON TX 77025
Brian Mueller director C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Paul F Truex director PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Charles V Olson officer: Chief Technology Officer 25801 INDUSTRIAL BLVD., SUITE B, HAYWARD CA 94545
Klara Dickinson officer: Chief Regulatory Officer C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Steven B Engle director C/O XOMA LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
James Pennington officer: Interim Chief Medical Officer 25801 INDUSTRIAL BLVD, SUITE B, HAYWARD CA 94545
Hislop Colin officer: Chief Medical Officer C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Sanford S Zweifach director 21720 23RD DRIVE SE, SUITE 150, BOTHELL WA 98021
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Christopher P. Lowe officer: CFO and Chief Business Officer 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Orbimed Capital Gp Iv Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Samuel D Isaly director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Anthera Pharmaceuticals (Anthera Pharmaceuticals) Headlines